VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

BMC Cancer · 2014 · PMC4094395 · PMID 24981311

Europe PMC DOI

hedged sentences

0.0730

closest p · 1.5× alpha

0.0990

boldest claim

The sentences

showed a trendp = 0.073so close (0.05 < p ≤ 0.1)

While CXCR4 negative patients showed a trend towards treatment benefit with FLO (Figure 3 A, p = 0.073), patients with strong CXCR expression survived longer under FLP treatment (Figure 3 B, p = 0.05).

also in 53,322 other papers

a strong trendp = 0.099so close (0.05 < p ≤ 0.1)

A strong trend in favour of the FLO-therapy was detected (Figure 2 A, p = 0.099), in terms of 5-year survival.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.